SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

RYZ101

BMY·BRISTOL MYERS SQUIBB CO
BULLISH
Drug Impact Rating4/10
Trial phase
Phase 3 (positive interim analysis completed)
Time to market
BMS plans to discuss a regulatory submission with the FDA following the positive Phase 3 interim analysis, but no timeline has been provided. If filed, a standard FDA review would take approximately 10-12 months, suggesting a potential approval in late 2027 or 2028 at the earliest.
Why 4/10
No hard dated binary catalyst (PDUFA or pivotal readout) is scheduled in the next ~12 months; the Phase 3 interim analysis was already reported on October 12, 2026, and BMS has only stated it will engage with the FDA on next steps without a timeline. At a diversified mega-cap pharma (~$126B market cap), RYZ101 is a small pipeline component, so the default impactScore of 4 applies.
Actionable Insight BULLISH

The next catalyst is BMS's engagement with the FDA to discuss a regulatory submission for RYZ101 in GEP-NETs, following the positive Phase 3 ACTION-1 interim analysis announced October 12, 2026. No PDUFA date has been set. Detailed efficacy and safety data from ACTION-1 are expected at a future medical meeting, which could provide further clarity on the magnitude of the PFS benefit. For a diversified mega-cap like BMY, RYZ101 is a pipeline positive but not a stock-moving binary event.

Price Chart

Loading chart...

Executive Summary

RYZ101 is a first-in-class alpha-emitting radiopharmaceutical (actinium-225 DOTATATE) developed by RayzeBio, which Bristol Myers Squibb (BMY) acquired for $4.1 billion in early 2024. On October 12, 2026, BMS announced that the Phase 3 ACTION-1 trial met its primary endpoint, showing statistically significant improvement in progression-free survival for patients with advanced GEP-NETs whose disease progressed after lutetium-177 (Lutathera) therapy. The FDA granted RYZ101 Orphan Drug Designation for GEP-NETs in August 2026. BMS plans to engage with the FDA on next steps toward a regulatory submission, though no PDUFA date has been set. For BMY, a diversified mega-cap pharma with $13B+ in quarterly revenue, RYZ101 is a positive pipeline development but not a company-defining catalyst.

How It Works

RYZ101 is a targeted radioactive drug. It combines a tumor-seeking peptide (DOTATATE, which binds to somatostatin receptors commonly found on neuroendocrine tumor cells) with a powerful alpha-emitting radioisotope called actinium-225. Once injected, the drug homes in on cancer cells and delivers a short-range, high-energy burst of alpha radiation that damages the cancer cell's DNA, killing it while largely sparing surrounding healthy tissue. This is similar in concept to Novartis's Lutathera but uses a different, more potent type of radiation (alpha particles instead of beta particles).

Trial Status

The Phase 3 ACTION-1 trial (NCT05477576) in SSTR-positive GEP-NETs that progressed after lutetium-177 therapy met its primary endpoint at a planned interim analysis on October 12, 2026, with statistically significant improvement in progression-free survival. Detailed results have not been disclosed and are expected at a future medical meeting. RYZ101 is also being studied in earlier-stage trials for HR+ metastatic breast cancer, extensive-stage small cell lung cancer, and meningioma.

The Two-Sided Case

▲ Bull Case4
RYZ101 is the first alpha-emitting radiopharmaceutical to succeed in a Phase 3 trial, a potential first-in-class and first-in-category milestone.
The ACTION-1 trial met its primary endpoint (PFS) with statistical significance in a high-need population: GEP-NET patients who progressed after lutetium-177 therapy, where no randomized Phase 3 data previously existed.
FDA granted Orphan Drug Designation for GEP-NETs in August 2026, which provides market exclusivity and development incentives.
BMS acquired RayzeBio for $4.1B specifically for this platform, signaling strong internal conviction and commitment to radiopharmaceuticals.
▼ Bear Case4
Detailed efficacy numbers (hazard ratio, median PFS) from ACTION-1 have not been disclosed, making it impossible to assess the magnitude of benefit versus standard of care.
RYZ101 is a small part of BMY's massive pipeline ($13B+ quarterly revenue). Even a successful approval would have limited impact on BMY's share price.
Manufacturing and supply-chain challenges for actinium-225 radiopharmaceuticals are significant; BMS is investing $170M+ in a new facility, but scaling remains unproven.
Competition from Novartis's Lutathera (lutetium-177 DOTATATE) and other emerging radiopharmaceuticals could limit RYZ101's commercial opportunity.

Upcoming Catalysts

  • Engagement with FDA to discuss regulatory submission pathway (timeline not specified)
  • Presentation of detailed ACTION-1 efficacy and safety data at a future medical meeting
  • Potential BLA/NDA submission to FDA (no date set)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report

Sources · 10

Hover a chip for the title
1 news.bms.com2 biospace.com3 biopharmaperspective.com4 news.bms.com5 fool.com6 targetedonc.com7 oncodaily.com8 businesswire.com9 stockanalysis.com10 marketbeat.com